Tribenzor sanctioned for those who don’t respond to other drugs
    MONDAY, July 26 (HealthDay News) -- Tribenzor, a three-in-one drug to treat high blood pressure, has been approved by the U.S. Food and Drug Administration.
    Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide. The combination medication was approved for people whose high blood pressure isn‘t well controlled on other combinations of anti-hypertension drugs.
    Daiichi Sankyo, based in Japan with U.S. headquarters in Parsippany, N.J., produces the newly approved drug.
    In a news release, the company said adverse reactions to once-daily Tribenzor could include dizziness, swelling, headache, fatigue, muscle spasms, nausea, diarrhea or infections of the respiratory or urinary tracts.
    http://www.nlm.nih.gov/medlineplus/news/fullstory_101478.html